5 Key Points for Pharma Marketers – Dec 23, 2025

Bristol Myers Squibb Challenges Inflation Reduction Act at Supreme Court

Pharmaceutical company Bristol Myers Squibb has become the second to question the Inflation Reduction Act before the Supreme Court. This direct challenge follows on the heels of the announcement by the Centers for Medicare and Medicaid Services of two compulsory payment models intended to reduce the cost of Medicare drugs. (Endpoints News)

After US Tariff Agreement, Roche Forecasts Increased Drug Prices in Switzerland

Following a tariff agreement with the U.S., Roche’s CEO has hinted at a rise in the price of drugs in Switzerland. This announcement comes in the wake of a series of agreements between the Trump administration and pharmaceutical companies last week. (Reuters)

Pharma Companies Delay Disclosure of Drug Prices

Pharmaceutical corporations and pharmacy benefit managers have successfully postponed the disclosure of actual medicine prices for one more year. Despite a federal law mandating them to reveal these prices five years ago, the actual cost of prescription drugs continues to remain a secret. (STAT News)

Proposed Update to US Vaccination Schedule Withdrawn

Health and Human Services Secretary Robert F. Kennedy Jr.’s proposal to bring the U.S. immunization schedule in line with Denmark’s was retracted. The vaccination schedule in Denmark recommends inoculation against only 10 of the 17 diseases on the list. (Politico)

The Future of Healthcare in 2026

What will the healthcare landscape look like in 2026? As it stands, Congress has ended the year without agreeing on a healthcare deal that could benefit Americans. (TIME)

For more insights into yesterday’s top pharmaceutical news, click here.